40 varieties are included in the collection of Fujian, and the consequences of touching 12 "prohibitions" are very serious

Medical Network News, March 22, On March 17, Fujian Province issued a notice on publicly soliciting opinions on the "Fujian Province Drug Centralized Procurement Document (Draft for Comment)".
Among the drugs that are mature in clinical use, 40 purchased varieties have been selected (see the detailed table at the end of the article for details)
.
Prior to this (February 2020), Fujian had launched the first batch of centralized drug purchases, and a total of 14 varieties including voriconazole and febuxostat were selected
.
This time can be said to be the second batch of centralized procurement of medicines in Fujian Province, and the procurement rules are basically the same as those of the first batch.
The document clearly divides the varieties into two quality levels, over-evaluated and non-over-evaluated, and is included in the key monitoring of medical insurance in Fujian Province.
Or focus on the drugs in the list.
If selected in this centralized purchase, it will be removed from the corresponding list
.
The centralized procurement of selected drugs strictly implements the "two-vote system" and encourages the implementation of the "one-vote system"
.
At the same time, it also pointed out that 12 kinds of situations are included in the list of violations.
Once a company violates the regulations, it will lose the qualification to participate in procurement activities in Fujian Province within 2 years.
This shows the power of the credit system for recruiting and purchasing
.

　　The following is the key content of the document:
　　Divided into two quality levels
with the same generic name, according to the relevant qualifications, it is divided into two groups A and B.
Group A is original research drugs, reference preparations, drugs that have passed (including deemed passed) consistency evaluation, new Classified approval of generic drugs, into the "Chinese listed Drug List collection" of FDA-approved drugs and medicines, in addition to drugs classified as group B
.
The agreed purchase volume of each category A and B is grouped and determined according to 70% of the pre-purchasing volume reported by public medical institutions (including the Fujian army, armed police medical institutions, and military medicinal material supply stations, the same below) in the province
.

　　Purchase execution instructions
All public medical institutions will give priority to the use of selected products in centralized procurement and ensure that the agreed procurement volume is completed.
In principle, the use of selected drugs shall not be less than 60% of the total use of the same group; as any of the two groups of generic names A and B If there is a set of flow marks, in principle, the usage of the corresponding products of the flow mark group shall not exceed the pre-purchasing amount of the flow mark group reported by the medical institution
.
By group B continue to perform the quantitation cycle performed by the quality and efficacy of drugs selected to evaluate the agreement
.
On the basis of prioritizing the use of the selected products, all public medical institutions can purchase other drugs with the same generic names at appropriate prices for the remaining amount
.
Calculated from the actual implementation date of the selected results, in principle 12 months
.
After expiration, the purchase period can be extended according to the actual conditions of purchase and supply, and the renewal period is in principle 12 months
.
If the agreed purchase quantity is completed in advance within the purchase cycle, the excess part of the selected enterprises shall still supply at the selected price
.
In the procurement cycle, relevant varieties are included in the national organization for centralized procurement with a quantity, and the results of the national procurement with a quantity are implemented as required
.

　　The selection rule in the grouping
distinguishes group A and group B bidding, and one bidding
.
The group with the number of companies ≥3: the one with the lowest quotation in the group will be selected, and 100% of the agreed purchase amount will be given to this group;
the group with the 　　number of companies ≤2 : the
group with the lowest quotation and the decrease (rounded to two decimal places, lower Same) The proposed selection that meets one of the following three conditions will be given 100% of the agreed purchase volume for this group: ①The decrease rate from high to low ranks in the top 50% of all groups (in case of indivisible integers); ②The same common name The other group of varieties (need to be three or more groups) has a decrease; ③It reaches 50% of the average decrease of three or more groups in all groups
.
The group with the lowest quotation and the decrease rate meets one of the following two conditions to be selected, the group will be given 50% of the agreed purchase volume: ①The decrease rate reaches 25% of the average decrease rate of three and above groups in all groups; ②The absolute decrease rate reaches 10%
.
The rest of the varieties are treated as flow standards, and the Provincial Pharmaceutical Procurement Center implements key monitoring of related products, and announces the purchase volume of each medical institution on a monthly basis, and includes it as a mandatory inspection item for medical insurance audit supervision
.
Decrease calculation basis: For products linked to the Internet in Fujian Province, the current provincial price is used as the calculation basis (if the company has the same generic name and the same drug route and multiple specifications are linked to the network, the decrease is calculated as low); not in Fujian Province The products on the net are calculated based on the current national lowest provincial centralized purchasing price of the company’s products with the same generic name and the same dosage form (excluding the price selected in volume purchases).
If the product has no historical price, the same group of products will be used in the province.
The current maximum selling price (lower when there are multiple price limits in the same group) is the calculation basis
.

　　When the lowest quotation is the same, the product selection principle is determined
from January 1 to December 31, 2020.
The same group of the same generic name product is selected for the application of the company with a large purchase in Fujian Province (the purchase volume of products of different specifications is converted and calculated in Fujian Province The data of the pharmaceutical equipment procurement platform shall prevail); if the products of the declared enterprise are all products that are not connected to the provincial pharmaceutical procurement platform, in the 2019 China Pharmaceutical Statistics Annual Report (Comprehensive Volume), "Industrial corporate entities are sorted by the main business income of the pharmaceutical industry" The top-ranked enterprises are selected among the declared varieties
.
If the price of the product with the same generic name is higher than that of the group A, the product of the group B to be selected shall be subject to price correction, and the quotation shall be adjusted to not exceed the price of the group A.
Otherwise, the qualification for the selection will be cancelled and the corresponding group will be deemed Flow mark
.

　　If the
products selected in the agreed procurement volume allocation are based on the agreed procurement volume corresponding to the preceding clauses of this document, and belong to the situation of group A flow standard (including no enterprise registration), the remaining agreed procurement volume of group A will be allocated to group B according to the following rules:

　　Those included in the list of violations will be canceled for 2 years
.
If the enterprises or distribution companies that participate in the procurement qualification declaration have the following behaviors, the relevant departments will be included in the "list of violations" if the circumstances are determined to be serious
.
Provide prescription kickbacks or other commercial bribes to carry out illegal promotional activities
.
Malicious declaration at a price lower than the cost disrupts the market order
.
Collusion in declarations to exclude fair competition from other declaring companies and harm the legitimate interests of the purchaser or other declaring companies
.
To win the election by bribing the purchaser and purchasing agency
.
Provide false certification documents and literature, or use other methods to falsify, defraud the selection
.
Failure to sign a volume purchase and sale contract within the prescribed time limit
.
The selected companies and distribution companies failed to implement distribution in accordance with the purchaser and the requirements of laws and regulations
.
After winning the election, give up the eligibility for selection
.
Failure to fulfill the promise of supply affects clinical use
.
Serious quality problems occurred after the selected drugs were selected
.
After the selected drug was selected, it was found that it seriously violated the promise made in the application materials during the specified random inspection or unannounced inspection
.
Other violations of laws and regulations
.
If the applying enterprise or distribution enterprise is included in the "list of violations", the relevant enterprise’s declaration, selection, and distribution qualifications for this centralized drug procurement shall be cancelled, and the qualifications for the declaration, selection and distribution of the drug’s centralized procurement shall be cancelled, and in accordance with the "Fujian Medical Security Bureau's Regulations on Establishing a Pharmaceutical Price and Recruitment Credit Evaluation System" Notice" (Min Medical Insurance [2021] No.
1)
.
At the same time, depending on the seriousness of the circumstances, the above-mentioned enterprises will be disqualified from participating in the drug procurement activities of Fujian Province within 2 years from the date of being included in the "violation list".

.